UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934

For the month of July, 2023

Commission File Number 001-40772

Cellebrite DI Ltd. (Translation of registrant's name into English)

94 Shlomo Shmelzer Road Petah Tikva 4970602, Israel (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F 🛛 Form 40-F 🗆

EXPLANATORY NOTE

Cellebrite DI Ltd. (the "**Company**") hereby announces that the shareholders of the Company approved all of the proposals brought before the annual general meeting of shareholders held on July 6, 2023 (the "**Meeting**"), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association, as described in the Proxy Statement which was attached as Exhibit 99.1 to the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (the "**SEC**"), on May 31, 2023, and sent in connection with the Meeting.

166,484,525 ordinary shares, representing approximately 84.96% of the issued and outstanding ordinary shares as of the record date, were present or represented by proxy at the Meeting.

This Report on Form 6-K is incorporated by reference into the Registrant's registration statements on Form S-8 (File No. 333-260878) and Form F-3 (File No. 333-259826) filed with the SEC on November 8, 2021 and September 13, 2022, respectively.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Cellebrite DI Ltd.

By: /s/ Ayala Berler Shapira

Ayala Berler Shapira General Counsel

July 10, 2023